The Pharmacology Core's mission is to provide state-of-the-art technology and expertise in bioanalysis, pharmacokinetics, and pharmacogenetics for evaluation of critical pharmacological endpoints in preclinical and eariy phase clinical studies. Two services, including pharmacokinetic/pharmacodynamic (PK/PD) sample processing and distribution service and bioanalysis service, have been provided since 2004. The PK/PD sample processing and distribution service provides support for clinical trials, including specimen transport, accountability, processing, storage, and distribution, in compliance with applicable Standard Operating Procedures (SOPs), IRB-approved protocols, and regulatory requirements. The bioanalysis service provides quantitative measurement of drugs and metabolites in biological samples (e.g., blood, plasma, serum, urine, or tissue samples) using high-performance liquid chromatography (HPLC) coupled with ultraviolet or fluorescence detection or tandem mass spectrometer detection (LC-MS/MS). In addition, three new service lines were recently developed in order to provide KCI investigators with comprehensive pharmacology support. These new services include: 1) bioanalytical methods development and validation service that includes evaluating all procedures for accuracy, precision, selectivity, sensitivity, reproducibility and stability of a particular HPLC or LC-MS/MS method;2) pharmacokinetic data analysis and modeling service that provides assistance in preclinical and clinical pharmacokinetic experimental design and protocol development as well as analysis and interpretation of pharmacokinetic data using traditional or population pharmacokinetic modeling approaches;and 3) pharmacogenetic analysis is a collaborative service with the Genomics Core that focuses on employing a candidate gene approach to examine the associations between common single nucleotide polymorphisms (SNPs) in selected genes (such as genes encoding drug metabolizing enzymes, transporters, or target receptors/enzymes) and PK parameters, PD effects, or clinical outcome (efficacy or toxicity) of clinical investigational anticancer agents. The Core is equipped with stateof- the-art analytical instruments such as LC-MS/MS. Available pharmacokinetic analysis software includes WinNonlin version 5.2 and NONMEM version 6. The laboratory is centrally located with convenient access forthe KCI investigators.

Public Health Relevance

The Pharmacology Core provides a centralized unit to facilitate cancer related clinical, translational, and basic science research with evaluation of critical pharmacological endpoints. The availability of this facility minimizes the cost and efforts of KCI investigators, and fosters interdisciplinary collaborations.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA022453-29
Application #
8350775
Study Section
Subcommittee G - Education (NCI)
Project Start
2011-09-06
Project End
2015-11-30
Budget Start
2011-09-06
Budget End
2011-11-30
Support Year
29
Fiscal Year
2011
Total Cost
$43,445
Indirect Cost
Name
Wayne State University
Department
Type
DUNS #
001962224
City
Detroit
State
MI
Country
United States
Zip Code
48202
Watza, Donovan; Purrington, Kristen S; Chen, Kang et al. (2017) Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy. J Thorac Dis 9:4162-4164
Eggly, Susan; Hamel, Lauren M; Foster, Tanina S et al. (2017) Randomized trial of a question prompt list to increase patient active participation during interactions with black patients and their oncologists. Patient Educ Couns 100:818-826
Bao, Bin; Mitrea, Cristina; Wijesinghe, Priyanga et al. (2017) Treating triple negative breast cancer cells with erlotinib plus a select antioxidant overcomes drug resistance by targeting cancer cell heterogeneity. Sci Rep 7:44125
Bernardo, Margarida M; Dzinic, Sijana H; Matta, Maria J et al. (2017) The Opportunity of Precision Medicine for Breast Cancer With Context-Sensitive Tumor Suppressor Maspin. J Cell Biochem 118:1639-1647
Soave, Claire L; Guerin, Tracey; Liu, Jinbao et al. (2017) Targeting the ubiquitin-proteasome system for cancer treatment: discovering novel inhibitors from nature and drug repurposing. Cancer Metastasis Rev 36:717-736
Jones, Carissa C; Bush, William S; Crawford, Dana C et al. (2017) Germline Genetic Variants and Lung Cancer Survival in African Americans. Cancer Epidemiol Biomarkers Prev 26:1288-1295
Bosnyák, Edit; Michelhaugh, Sharon K; Klinger, Neil V et al. (2017) Prognostic Molecular and Imaging Biomarkers in Primary Glioblastoma. Clin Nucl Med 42:341-347
Ben Khedher, Soumaya; Neri, Monica; Papadopoulos, Alexandra et al. (2017) Menstrual and reproductive factors and lung cancer risk: A pooled analysis from the international lung cancer consortium. Int J Cancer 141:309-323
Tan, Zhijing; Nie, Song; McDermott, Sean P et al. (2017) Single Amino Acid Variant Profiles of Subpopulations in the MCF-7 Breast Cancer Cell Line. J Proteome Res 16:842-851
Embogama, D Maheeka; Pflum, Mary Kay H (2017) K-BILDS: A Kinase Substrate Discovery Tool. Chembiochem 18:136-141

Showing the most recent 10 out of 726 publications